Such was the case for a patient receiving MEK inhibitor therapy for metastatic melanoma who experienced vision loss, pain, and foreign body sensation in both eyes 3 months after the initiation of MEK inhibitor therapy35 (Table 1). This evidence concerns the gene MAP2K7 and metastatic melanoma.